Consolidation therapy with high-dose cyclophosphamide (HDC) reduces minimal residual disease in patients with chronic lymphocytic leukemia (CLL) treated with fludarabine as induction therapy.

被引：0
|
作者：
Weiss, M [1 ]
Glenn, M [1 ]
Maslak, P [1 ]
Rahman, Z [1 ]
Megherian, L [1 ]
Noy, A [1 ]
Zelenetz, A [1 ]
Scheinberg, D [1 ]
Golde, D [1 ]
机构：
[1] MEM SLOAN KETTERING CANC CTR,DIV HEMATOL ONCOL,NEW YORK,NY 10021
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1911 / 1911
页数：1
相关论文
共 50 条
  • [1] Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy
    Weiss, MA
    Glenn, M
    Maslak, P
    Rahman, Z
    Noy, A
    Zelenetz, A
    Scheinberg, DA
    Golde, DW
    LEUKEMIA, 2000, 14 (09) : 1577 - 1582
  • [2] Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy
    MA Weiss
    M Glenn
    P Maslak
    Z Rahman
    A Noy
    A Zelenetz
    DA Scheinberg
    DW Golde
    Leukemia, 2000, 14 : 1577 - 1582
  • [3] Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL)
    OBrien, S
    Kantarjian, H
    Beran, M
    Lerner, S
    Gilbreath, J
    Keating, MJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 453 - 453
  • [4] Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL).
    OBrien, S
    Kantarjian, H
    Beran, M
    Freireich, E
    Komblau, S
    Koller, C
    Lerner, S
    Gilbreath, J
    Keating, M
    BLOOD, 1996, 88 (10) : 1910 - 1910
  • [5] Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab induces a high incidence of complete response in patients with chronic lymphocytic leukemia (CLL).
    Lamanna, N
    Weiss, MA
    Maslak, PG
    Gencarelli, AN
    Scheinberg, DA
    Horgan, D
    BLOOD, 2003, 102 (11) : 440A - 440A
  • [6] Immune anemias in patients with chronic lymphocytic leukemia treated with chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy.
    Borthakur, G.
    O'Brien, S.
    Wierda, W. G.
    Thomas, D. A.
    Cortes, J. E.
    Kantarjian, H.
    Lerner, S.
    Keating, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 361S - 361S
  • [7] Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL).
    Garcia-Manero, G
    O'Brien, S
    Cortes, J
    Giles, F
    Faderl, S
    Lerner, S
    Albitar, M
    Kantarjian, HM
    Keating, MJ
    BLOOD, 2000, 96 (11) : 757A - 757A
  • [8] High-dose therapy with stem cell support in 7 patients with chronic lymphocytic leukemia (CLL), pretreated with 2 or 3 lines of therapy including fludarabine
    Mahe, B
    Milpied, N
    Bulabois, CE
    JugeMorineau, N
    Moreau, P
    Harousseau, IL
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 318 - 318
  • [9] Minimal Residual Disease Stratification in Fludarabine Ccyclophosphamide Rituximab (FCR) Therapy in Chronic Lymphocytic Leukaemia (CLL
    Hayat, Amjad
    O'Brien, David
    Quinn, Fiona
    Keane, Fionnuala
    Parker, Imelda
    Kelly, Johanna
    Wieczorkowska, Marzena
    Crotty, Gerard
    Leahy, Maeve
    Enright, Helen
    Hennessy, Brian
    Cahill, Mary
    Vandenberghe, Elisabeth A.
    BLOOD, 2012, 120 (21)
  • [10] Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia
    Short, Nicholas J.
    Keating, Michael J.
    Wierda, William G.
    Faderl, Stefan
    Ferrajoli, Alessandra
    Estrov, Zeev
    Smith, Susan C.
    O'Brien, Susan M.
    CANCER, 2015, 121 (21) : 3869 - 3876
12345